Opko Health (OPK) - FREE Research Report Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 14,800 shares at $9.93 on Nov. 26, 2013. Following this transaction, the CEO & Chairman owned 137.2 million shares meaning that the stake was reduced by 0.01% with the 14,800 share transaction. The shares most recently traded at $10.33, up $0.40, or 3.86% since the insider transaction. The average volume for Opko Health has been 5.1 million shares per day over the past 30 days. Opko Health has a market cap of $4.0 billion and is part of the health care sector and health services industry. Shares are up 106.24% year to date as of the close of trading on Tuesday. Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on OPK - FREETheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.